0 item $0.00

In current clinical practice, effectively managing thrombotic diseases like heart attack and stroke presents a significant challenge due to the delicate balance required between preventing blood clot formation and minimising bleeding complications. To address this challenge, we are leveraging biotechnological tools to develop recombinant antibody-drug fusion constructs. These innovative constructs are designed to selectively target and inhibit specific molecules and pathways involved in clot formation.

By doing so, they offer the potential to reduce the risk of bleeding complications commonly associated with traditional anti-thrombotic or anti-platelet drugs. Additionally, we are exploring novel approaches, such as the use of tailored nanoparticles, to precisely direct the transport and enrichment of drugs. Our dedicated research team is heavily invested in the biotechnological advancement of these antibody-drug fusion constructs, recognising their potential for clinical translation and their significant contributions to the field.

Student research opportunities

Beginning your research career with one of Australia's largest medical research institutes provides unique opportunities for Masters, Honours and PhD students.

Find out more